Detail akcie NeoGenomics Inc online

Business Summary: NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
Financial Summary: BRIEF: For the six months ended 30 June 2024, NeoGenomics, Inc. revenues increased 13% to $320.7M. Net loss decreased 17% to $45.7M. Revenues reflect Clinical Services segment increase of 16% to $275.9M, Advanced Diagnostics segment increase of 89% to $44.8M. Lower net loss reflects General and administrative decrease of 46% to $55.7M (expense), Total Amort of Intangibles-excl Goodwill decrease of 56% to $3.5M (expense).